electroCore, Inc. (ECOR)

[Bigspirit1]

Agreed. Frank is a good man. He has been successful before and he will be successful again. The negatives to the PBM strategy are cost and time. The hiring of MSL’s are expensive at first. These elements are classic big pharma and work in the long run. Unfortunately that is not the environment.

With a company like this you have to take small steps first or simultaneously with the big strategy. There are many tactics that can build a customer base that offer high returns on investment in the shorter term. Right now they need more customers driven to more docs. There are large areas where the earliest adopters have not been contacted. The successful outcome of this product should be spreading like wildfire across sufferers.

After spending decades in big pharma and a half dozen years in micro/nano ventures, I can assure you that the picture and focus are very different for the same product. While licensing may be an option, the lack of revenue will negatively affect the price. They need people like us to show them the other options.